Pfizer
Business & Industry
- Pfizer launches cost savings program on TrumpRx lowering drug costs for millions of Americans
- Sanofi announces the signing of a share buyback mandate for up to €1 billion
- AstraZeneca begins trading on the New York Stock Exchange
- Abbott increases quarterly dividend for 54th consecutive year
- Bristol Myers Squibb announces collaboration with Microsoft to advance AI-driven early detection of lung cancer
Research & Development
- Multiple myeloma: Established cancer drug reactivates immunotherapy
- Why people won't quit a weight loss drug - even when it makes them feel sick
- AI that understands chemical principles... Accelerating the development of new drugs and materials
- Statins do not cause the majority of side effects listed in package leaflets
- Innovative ‘poop pills’ show promising results in clinical trials for multiple types of cancer
- How a heart medication could unlock a new targeted approach in lymphoma
- A broken DNA repair tool accelerates aging
Conferences & Events
- SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
- SAE Media Group's 6th annual 3D Cell Culture Conference
- CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
- 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
- CPHI Excellence in Pharma Award Winners 2022
- CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
- CPHI Frankfurt 2022: Global pharma confidence hits record high in the annual CPHI Pharma Index
Regulatory Affairs
- FDA expands artificial intelligence capabilities with agentic AI deployment
- FDA approves first gene therapy for treatment of aromatic L-amino acid decarboxylase deficiency
- FDA approves new treatment for hemophilia A or B
- FDA approves nasal spray influenza vaccine for self- or caregiver-administration
- FDA approves first nasal spray for treatment of anaphylaxis